Pheno

Quick links to important sections

Pheno

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pheno

Quick Facts: Phenobarbital

Property Description
Active ingredient Phenobarbital (Phenobarbitone)
Form Tablet, Oral solution, Injectable solution
Pharmacological class Long-acting Barbiturate, Anticonvulsant
Common use Management of seizure disorders
Origin Synthetic (Barbituric acid derivative)

What Type of Medicine is Pheno? (Definition and Classification)

Pheno is used contextually as a name for the active ingredient Phenobarbital, which is formally classified as a long-acting barbiturate and a fundamental anticonvulsant (anti-epileptic drug). The active substance is identified by its complex chemical structure, a synthetic compound derived from Barbituric acid. This medication is a prescription-only medicine designed for sustained stability in the central nervous system. Its identity as a long-acting substance is a key differentiating factor, making it uniquely suited for chronic condition management and providing continuous neuronal stabilization, a characteristic recognized in medical classifications. This confirms the medication is a resource for long-term seizure management.


Composition, Origin, and Available Forms

Phenobarbital is a synthetic compound that functions as a single-ingredient product, which ensures predictable therapeutic effects confined to the known pharmacodynamics of this agent. This single-entity composition differentiates it from many modern antiepileptic drugs that are often used in combination formulas. Phenobarbital is available in different physical presentations, including the solid tablet and the liquid oral solution or injectable solution (ampoule). These forms allow the drug to be administered orally for routine management or parenterally (intramuscularly/intravenously) for rapid stabilization.


Phenobarbital's General Therapeutic Purpose

The general purpose of Phenobarbital is to function as a powerful Central Nervous System (CNS) depressant to manage the brain's electrical activity. It achieves this by reducing excessive neuronal excitability and effectively raising the seizure threshold. This systemic dampening of electrical signals is the primary mechanism by which the drug is employed to establish and maintain control over chronic electrical disturbances in the brain, offering a crucial long-term means of regulating abnormal activity. Phenobarbital is utilized as a foundational agent for the control of generalized tonic-clonic and partial seizures, playing a role in stabilizing key brain functions.

Regulatory References

  1. WHO Essential Medicines List for Phenobarbital
  2. Phenobarbital FDA-Approved Product Labeling

What side effects are possible with Pheno?

Possible Side Effects and Safety Information

The safety profile of Phenobarbital (Pheno) is formally defined by regulatory authorities based on clinical and post-marketing data, categorizing adverse reactions by the organ system affected and their reported frequency.

Commonly Documented Adverse Reactions

The most frequently observed effects are related to the Central Nervous System (CNS), often classified as Common in official labeling. These include drowsiness, sedation, dizziness, and residual confusion. In the pediatric population, a distinct reaction of paradoxical excitement and hyperactivity is commonly documented.

System-Organ Class (SOC) Safety Domains

Adverse reactions are officially grouped by the system they affect, including the Nervous System (ataxia, nystagmus), Psychiatric Disorders (depression, nervousness), Skin and Subcutaneous Tissue Disorders, and the Hepatobiliary System (cholestasis, hepatitis).

Serious Adverse Reactions and Constraints

The regulatory label specifically documents the risk of rare but life-threatening conditions, known as Severe Cutaneous Adverse Reactions (SCARs), which include Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The risk of suicidal ideation and behavior is also a documented serious adverse reaction. Furthermore, the potential for physiological and psychological dependence is a recognized risk, particularly with long-term use.

Phenobarbital is formally contraindicated in conditions such as severe respiratory depression, severe hepatic or renal impairment, and acute intermittent porphyria. Specific considerations are noted for older adults, who may experience heightened confusion and memory issues, and for use during pregnancy and lactation.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Phenobarbital (Pheno) is formally documented in regulatory sources as a severe and potentially life-threatening event requiring immediate medical attention.


Documented Overdose Manifestations

The primary presentation is dose-dependent Central Nervous System (CNS) Depression, progressing through states of profound drowsiness, confusion, stupor, and deep coma. The official labeling lists other signs such as slurred speech and ataxia (loss of coordination).

Life-threatening outcomes involve compromise to the respiratory and cardiovascular systems. These include severe respiratory depression, leading to apnea and potential respiratory arrest, as well as profound hypotension and circulatory collapse. The official documentation states that overdose can result in death.


Required Emergency Action

If overdose is suspected or if the person has collapsed, has trouble breathing, or cannot be awakened, you must seek immediate medical attention and contact emergency services. The regulatory instructions emphasize the need for meticulous symptomatic and supportive therapy, including protecting the patient's airway and maintaining vital signs.

Treatment procedures documented in official sources may include enhanced elimination techniques like gastric lavage, administration of activated charcoal, and in severe cases, hemodialysis or hemoperfusion. No specific antidote is known for Phenobarbital overdose according to regulatory labeling.

Therapeutic Uses of Pheno

Phenobarbital is considered relevant for managing symptoms, primarily those associated with excessive and abnormal CNS electrical activity, and is applied across domains where additional symptomatic support is needed.

This medication is primarily used to control seizures and to relieve anxiety. It is relevant for sustained control over symptoms of increased neurological activity associated with recurrent or episodic manifestations, and is commonly used across conditions presenting with recurrent or episodic manifestations, where symptoms create noticeable functional strain. It is also a commonly used agent in acute seizure states such as Status Epilepticus, relevant for easing the burden of these sudden, severe manifestations, and assists with maintaining functional stability. The medication plays a role in managing symptoms related to heightened physiological activity in withdrawal syndromes and may assist in providing symptomatic relief that helps patients cope more steadily during the acute symptomatic phases. It is applied when appropriate in settings marked by temporary physiological imbalance.


Key Therapeutic Domains

Phenobarbital is commonly used for managing symptoms associated with seizure disorders in chronic management, for emergency treatment of sustained convulsive episodes, and to address severe withdrawal symptoms (including those linked to alcohol and benzodiazepines, and Neonatal Abstinence Syndrome).


Quick Fact: Relief for Convulsive Symptoms

Phenobarbital may be part of symptomatic management for symptoms of increased neurological activity, which helps address symptom clusters that may become intense or disruptive, especially when used in clinical settings that involve acute or disruptive symptom patterns.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Pheno (Phenobarbital)?

Official regulatory documents define strict population eligibility for Pheno based on patient demographics, organ function, and specific health conditions.

Contraindicated Populations (Must Not Use)

Phenobarbital is absolutely contraindicated for patients with a known hypersensitivity to barbiturates or any component of the formulation. Use is prohibited in patients with acute intermittent porphyria, marked impairment of liver function (severe hepatic damage), or severe obstructive respiratory disease

. The medicine is also contraindicated for individuals with a history of sedative/hypnotic drug dependence.


Restricted and Conditional Use

Certain populations must use Phenobarbital with great caution and typically a reduced dosage:

  • Geriatric Patients: Older adults require caution due to increased sensitivity and risk of confusion.
  • Organ Dysfunction: Use is restricted in patients with severe renal impairment or decreased liver function.
  • Pregnancy: The drug is Pregnancy Category D and should only be used if clearly needed, due to evidence of fetal risk. Women of childbearing potential are officially advised to use highly effective contraception.

It is used for the management of specific seizure types in patients of all ages, but caution is required in pediatric use due to the risk of paradoxical excitement.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Phenobarbital's interaction profile is primarily defined by its role as a potent inducer of hepatic microsomal enzymes (e.g., the CYP450 system). This enzyme induction accelerates the metabolism and clearance of many co-administered medicines, reducing their concentrations in the body.

Documented Pharmacokinetic Interactions

Phenobarbital may reduce the effectiveness of several drug classes, including Oral Anticoagulants (such as Warfarin), Corticosteroids, and Hormonal Contraceptives (leading to potential failure). It also accelerates the clearance of certain Antibacterials (like Doxycycline) and other Antiepileptics (like Lamotrigine).

Conversely, some agents, such as Valproate (Valproic Acid), are documented to reduce Phenobarbital’s clearance, leading to increased Phenobarbital serum levels.

Contraindicated and Pharmacodynamic Risks

Certain combinations are subject to strict regulatory constraints:

  • Formal Contraindications: Co-administration with Voriconazole is prohibited due to the significant reduction in Voriconazole plasma concentrations.
  • Opioids and CNS Depressants: Combining Phenobarbital with Opioids is reserved for cases where alternatives are inadequate due to the risk of profound sedation and respiratory depression. Alcohol also produces an additive central nervous system depressant effect.

Time-Based and Population-Specific Notes

The interaction with Telithromycin requires co-administration to be avoided during therapy and for two weeks after discontinuation. For women of childbearing potential, non-hormonal contraception must be used during and for two months following treatment due to the documented risk of hormonal contraceptive failure.

Mechanism of Action

Phenobarbital’s primary pharmacodynamic mechanism is mediated by its action as a positive allosteric modulator on the GABAA receptor complex in the central nervous system ( CNS). This receptor is the principal target for inhibitory neurotransmission. By binding to an allosteric site, Phenobarbital prolongs the opening time of the receptor’s integral chloride ion ( Cl^-) channel, enhancing the inhibitory effects of endogenous GABA.

The resulting sustained influx of negative Cl^- ions causes the postsynaptic neuron to hyperpolarize, thereby increasing its electrical stability and resistance to excitation. This cellular stabilization creates a systemic dampening effect that restricts the widespread propagation of rapid electrical signals. The drug also contributes to this effect via a secondary mechanism involving the inhibition of excitatory glutamate receptor activity. The combined effect elevates the seizure threshold of the brain tissue, limiting overall neuronal excitability. This broad CNS depressant mechanism is functionally constrained by its dose-dependent suppression of the medullary respiratory center and its reduced functional influence over specific neuronal circuits, such as those involved in absence-type discharges.

Dosage and Administration Information

Administration Route and Dosing Regimens

Phenobarbital is available for administration via the oral route (as a tablet or solution) for chronic management and via parenteral routes (intravenous or intramuscular injection) for acute care settings. The method of administration is governed by the required speed of action and the clinical context.

For maintenance use, the long half-life of phenobarbital supports a once-daily dosing schedule, frequently taken at night to help sustain plasma concentrations within the specific therapeutic range (e.g., 10–40 mug/mL). Standard adult maintenance doses typically range from 60 mg to 180 mg daily. Alternatively, some regimens specify dividing the dose into two or three daily portions.

In acute, emergent situations, an intravenous loading dose of 15 mg/kg to 20 mg/kg may be administered. During IV injection, the rate must be controlled and generally should not exceed 60 mg per minute in adults.


Procedural and Population-Specific Use

Official instructions indicate that phenobarbital can be taken with or without food; however, consistency in daily timing is advised. Dosage is highly individualized and relies on regular monitoring to guide adjustments.

Specific guidelines mandate a reduced dosage for older or debilitated adults due to increased sensitivity and slower clearance rates. Dosing for pediatric patients is typically calculated by body weight, often ranging from 5 to 8 mg/kg daily. When discontinuing treatment, the dosage must always be gradually reduced over a designated period to avoid the sudden onset of neurological complications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Phenobarbital

Evidence for Use in Chronic Seizure Disorders

Research evidence for Phenobarbital in seizure disorders is founded on a foundation of both Randomized Controlled Trials (RCTs) and decades of long-term observational studies. These studies were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms. The research monitored various patient populations, including adults and children, and research monitored the use of Phenobarbital in contexts such as generalized tonic-clonic and partial seizures.

The studies examined outcomes related to episodic or acute changes, such as the rate at which patients achieved seizure freedom or a specific reduction in seizure frequency in the study populations. Findings describe patterns observed in the studies and research describes how symptoms evolved in the observed populations. Researchers have also explored comparative data by examining Phenobarbital against other agents in trials.

It is important to note that the evidence quality varies across studies, particularly among older trials, which may have used less rigorous methods than modern research. Furthermore, there is limited information for long-term outcomes regarding behavioral changes and cognitive function, especially in children, where findings were mixed and evidence contributes to the broader evidence landscape.


Evidence for Use in Acute Seizure States

The evidence is founded on Randomized Clinical Trials (RCTs) and Systematic Reviews that focused on patients experiencing convulsive status epilepticus who did not achieve control with first-line agents. Research examined temporary physiological imbalance in both adult and pediatric populations.

Studies monitored outcomes describing episodic or acute changes, specifically the time required to achieve cessation of seizure activity and the overall rate of seizure termination within defined time intervals. Research highlights changes measured during the study period, showing patterns related to seizure activity. Findings also described neurological outcomes observed at short-term follow-up after the acute episode.

Comparative evidence is lacking for some of the newer treatment options, meaning the research often focused on comparisons with other agents. While the drug was evaluated in some studies, comprehensive data comparing it to all modern alternatives in large-scale RCTs remain insufficient.

Key Studies & References

  1. A Comparison of Parenteral Phenobarbital vs. Parenteral Phenytoin as Second-Line Management for Pediatric Convulsive Status Epilepticus in a Resource-Limited Setting - Frontiers
  2. Phenobarbital for Alcohol Withdrawal Syndrome Dosing Guidelines (Example Clinical Protocol)
  3. Alcohol Withdrawal Prevention & Treatment | McGovern Medical School - UTHealth Houston (Clinical Review)
  4. Phenobarbital - StatPearls - NCBI Bookshelf - NIH (General Drug Monograph)
  5. Label: PHENOBARBITAL tablet - DailyMed - NIH (FDA-Authorized Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Pheno (FAQ)

Q: Is Pheno the same kind of drug as other common treatments for the condition?

A: Official documents classify Pheno (Phenobarbital) as a long-acting barbiturate and a fundamental anticonvulsant (anti-epileptic drug). Its mechanism of action is described as enhancing GABA A receptor activity in the central nervous system. While this mechanism is shared by some agents used to manage seizures, the barbiturate class distinguishes it from many modern treatment options.

Q: How long does it usually take to notice an effect from Pheno?

A: The time it takes for the body to reach stable drug levels, known as steady-state concentration, is officially described as requiring approximately 3 to 4 weeks of therapy. This is a result of the drug's long plasma half-life. When used intravenously for acute situations, the onset of action is documented as being much faster, often within minutes.

Q: Does Pheno have a risk of dependency or addiction?

A: Official labeling documents confirm that the use of Phenobarbital carries a documented risk of both physiological and psychological dependence, particularly when it is used for long periods. It is listed as a controlled substance, and official documents note the importance of using the medication strictly as described by the prescriber.

Q: Can Pheno be taken long-term?

A: Phenobarbital is officially described as a long-acting substance well-suited for the chronic management of seizure conditions and is used for sustained therapy. However, official documents also note that the potential for dependence is a risk factor associated with long-term use.

Q: What happens if I forget to take a dose of Pheno?

A: Official protocol describes that the missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory warnings state that extra medication is not to be used to make up for a missed dose.

Q: Is Pheno safe to use for older adults?

A: Official guidelines indicate that a reduced dosage is often specified for older or debilitated adults due to increased sensitivity and slower clearance rates. Confusion and memory issues are documented risks that may be heightened in this population, and use in this population requires a specific dose reduction and monitoring as described in official guidelines.

Q: Can children or teenagers take Pheno?

A: Phenobarbital is officially used for managing specific seizure types in patients of all ages, with dosage often calculated based on body weight for children. Official safety documents note a distinct reaction in the pediatric population called paradoxical excitement and hyperactivity.

Q: Can Pheno affect my ability to drive or operate machinery?

A: Official instructions caution that Phenobarbital may impair the mental and/or physical abilities needed to perform hazardous tasks, such as driving a car or operating heavy machinery. This warning is based on the common central nervous system effects of the drug, which include drowsiness, sedation, and dizziness. Official instructions caution that this effect may occur.

Q: Does Pheno interact with supplements like vitamins or herbal remedies?

A: Phenobarbital is known to accelerate the metabolism and clearance of many co-administered medicines through enzyme induction. While specific supplements may not be universally listed, regulatory documents describe the importance of informing the prescriber of all co-administered supplements and herbal products.

Q: Is it safe to stop taking Pheno suddenly?

A: Official documents state that when discontinuing treatment, dosage reduction should be gradual over a designated period. This is necessary to avoid the sudden onset of neurological complications that can occur from abrupt cessation.

Q: What is the difference between Pheno and the generic version?

A: The name Pheno is used contextually as a name for the active ingredient Phenobarbital. The generic version contains the identical active ingredient. The product is officially defined as a single-ingredient drug, meaning the generic and brand names share the same fundamental composition.

Q: Does Pheno affect sleep patterns?

A: Drowsiness and sedation are officially listed as common side effects of Phenobarbital. Official documents describe that, due to its effects as a central nervous system depressant and its long duration of action, it may interfere with normal sleep cycles.

Q: Are there any blood tests required while taking Pheno?

A: Official guidance notes that the drug dosage is highly individualized and relies on regular monitoring to guide adjustments. Specific tests are used to measure the amount of Phenobarbital in the blood to ensure it remains within the established therapeutic range (the level needed to achieve the intended effect).

Q: How long does Pheno stay in your system after stopping it?

A: Phenobarbital is classified as a long-acting drug. Its plasma half-life—the time required for half the drug to be eliminated from the body—is officially described as ranging from 53 to 118 hours (approximately two to five days) in adults. Full clearance from the system requires multiple half-lives.

Q: Can Pheno affect blood pressure?

A: Regulatory adverse reaction texts document that the intravenous administration of Phenobarbital, which is typically used in acute settings, may result in hypotension (low blood pressure). This is a known risk, particularly in certain susceptible patient populations.

How should Pheno be stored and disposed of?

How to Store and Dispose of Pheno

Phenobarbital is an officially classified controlled substance, and its storage and disposal requirements are strictly defined by regulatory authorities.

Official Storage and Handling

Requirement Description
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Security Must be stored locked up in a secure location and kept in its original container with the lid tightly closed.
Protection Protect from direct sunlight and moisture.

Disposal Instructions

Unused or expired Phenobarbital must be disposed of carefully to prevent misuse and environmental harm.

  • Secure Disposal: The best method is to utilize an official drug take-back program (e.g., mail-back envelopes or drop-off kiosks) that complies with controlled substance regulations.
  • Household Disposal: If no take-back option is available, the medicine must be removed from its container, mixed with an unappealing substance (such as dirt or used coffee grounds), placed into a sealable bag or container, and then thrown into the household trash.
  • Environmental: Avoid flushing down the toilet or sinking and prevent release into the environment, including drains and waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pheno found in:

A-Z Index: